EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1565-1568, 2014
DC‑CIK biotherapy for a recurrent benign lymphoepithelial lesion of the salivary gland: A case report and literature review DEJUN XING* and YUEMING ZHAO* Department of Medical Oncology, Jilin Cancer Hospital, Changchun, Jilin 130012, P.R. China Received April 2, 2014; Accepted August 5, 2014 DOI: 10.3892/etm.2014.1937 Abstract. A benign lymphoepithelial lesion (BLEL) is an idiopathic inflammation of the parotid gland, characterized by hyperplasia, lymphocyte infiltration and the formation of epimyoepithelial islands, as well as atrophy of the gland parenchyma. Common treatment methods include immunosuppression and glucocorticoid therapies, in addition to surgical dissections. Cytokine‑induced killer (CIK) cells sensitized to specific antigens by dendritic cells (DCs) are used in DC‑CIK biotherapy. The present study reports the case of a 22‑year‑old female suffering from a postoperative recurrent BLEL on the left parotid gland, which was gradually increasing. Following initial unsuccessful conservative treatment attempts, a 10‑day course of DC‑CIK therapy was initiated, after which the lesion in the gland area was reduced in size and local infection and skin ulcerations were improved. DC‑CIK biotherapy was continued for three months (four sessions of 10‑day treatments with a 10‑day break in between) until the lesion disappeared and the skin ulceration was healed. Computerized tomography scans of the parotid gland revealed complete remission of the primary lesion and recovery of the bone destruction. The patient was discharged and remained stable with no sign of recurrence during a 10‑month follow‑up period. In the present case report, a successful DC‑CIK adoptive cellular immunotherapy treatment for a BLEL was described for the first time. Introduction Benign lymphoepithelial lesions (BLELs) show three histological characteristics: Hyperplasia and infiltration of lymphocytes into the gland, atrophy of the gland parenchyma
Correspondence to: Professor Dejun Xing or Miss. Yueming Zhao, Department of Medical Oncology, Jilin Cancer Hospital, 1018 Huguang Road, Changchun, Jilin 130012, P.R. China E‑mail: [email protected] E‑mail: [email protected] *
Contributed equally
Key words: benign lymphoepithelial lesion, dendritic cell, cytokine‑induced killer cell, adoptive cellular immunotherapy
and hyperplasia and infiltration of epimyoepithelial islands in the gland duct. In 1952, Godwin denominated the condition as ʻbenign lymphoepithelial lesionʼ (1), which was newly classified as a benign salivary gland tumor in 1991 (2). BLELs were not considered to be tumors, but rather a type of reactive hyperplasia, characterized by a benign, long progression, which was not life‑threatening and was rarely malignant in patients. BLELs appear mainly in unilateral or bilateral parotid tissues and the submandibular gland; however, cases of lymphoepithelial lesions of the salivary gland are rare, comprising
DC‑CIK biotherapy for a recurrent benign lymphoepithelial lesion of the salivary gland: A case report and literature review DEJUN XING* and YUEMING ZHAO* Department of Medical Oncology, Jilin Cancer Hospital, Changchun, Jilin 130012, P.R. China Received April 2, 2014; Accepted August 5, 2014 DOI: 10.3892/etm.2014.1937 Abstract. A benign lymphoepithelial lesion (BLEL) is an idiopathic inflammation of the parotid gland, characterized by hyperplasia, lymphocyte infiltration and the formation of epimyoepithelial islands, as well as atrophy of the gland parenchyma. Common treatment methods include immunosuppression and glucocorticoid therapies, in addition to surgical dissections. Cytokine‑induced killer (CIK) cells sensitized to specific antigens by dendritic cells (DCs) are used in DC‑CIK biotherapy. The present study reports the case of a 22‑year‑old female suffering from a postoperative recurrent BLEL on the left parotid gland, which was gradually increasing. Following initial unsuccessful conservative treatment attempts, a 10‑day course of DC‑CIK therapy was initiated, after which the lesion in the gland area was reduced in size and local infection and skin ulcerations were improved. DC‑CIK biotherapy was continued for three months (four sessions of 10‑day treatments with a 10‑day break in between) until the lesion disappeared and the skin ulceration was healed. Computerized tomography scans of the parotid gland revealed complete remission of the primary lesion and recovery of the bone destruction. The patient was discharged and remained stable with no sign of recurrence during a 10‑month follow‑up period. In the present case report, a successful DC‑CIK adoptive cellular immunotherapy treatment for a BLEL was described for the first time. Introduction Benign lymphoepithelial lesions (BLELs) show three histological characteristics: Hyperplasia and infiltration of lymphocytes into the gland, atrophy of the gland parenchyma
Correspondence to: Professor Dejun Xing or Miss. Yueming Zhao, Department of Medical Oncology, Jilin Cancer Hospital, 1018 Huguang Road, Changchun, Jilin 130012, P.R. China E‑mail: [email protected] E‑mail: [email protected] *
Contributed equally
Key words: benign lymphoepithelial lesion, dendritic cell, cytokine‑induced killer cell, adoptive cellular immunotherapy
and hyperplasia and infiltration of epimyoepithelial islands in the gland duct. In 1952, Godwin denominated the condition as ʻbenign lymphoepithelial lesionʼ (1), which was newly classified as a benign salivary gland tumor in 1991 (2). BLELs were not considered to be tumors, but rather a type of reactive hyperplasia, characterized by a benign, long progression, which was not life‑threatening and was rarely malignant in patients. BLELs appear mainly in unilateral or bilateral parotid tissues and the submandibular gland; however, cases of lymphoepithelial lesions of the salivary gland are rare, comprising
